PCOS: phenotypes, visceral obesity and a personalized approach in the prescription of COC





polycystic ovary syndrome, PCOS, obesity, visceral obesity, combined oral contraceptives, insulin resistance, dyslipidemia, Belara


Polycystic ovary syndrome (PCOS) is a complex of endocrine disease with several phenotypes, which determines the difficulties in its diagnostics (“diagnosis of exceptions”). This is an interdisciplinary disease, as the consequences of this syndrome can be serious (infertility, cardiovascular diseases, diabetes mellitus and their complications). The reason for this is the fact that PCOS occurs with metabolic disorders, manifested as violations of carbohydrate and fat metabolism.

Determination of specific phenotypes of women with PCOS are justified from the point of metabolism. Metabolic disorders in PCOS can prevail throughout life. At the initial stages, these changes may be invisible and not diagnosed. PCOS is often characterized by the presence of insulin resistance and is associated with hyperinsulinemia in most obese patients.

PCOS can occur with various forms of obesity, the most important is visceral obesity. This connected with the fact that visceral obesity may present in women with PCOS with no elevated body mass index. Therefore, timely diagnostics of obesity, especially visceral, determines the health consequences of this syndrome.

There are certain difficulties in the diagnostics of visceral obesity, but many of them are surmountable in modern conditions. Women with PCOS need the use combined oral contraceptives with both contraceptive and curative purposes. Therefore, the choice of the medicine depending on the clinical situation, the peculiarities of redistribution of adipose tissue is important in clinical practice. With the correct choice of COC, there will be no significant adverse effects on the metabolic profile of patients with PCOS and, possibly, a positive effect on their lipid profile will be observed. And yet, weight loss can lead to spontaneous ovulation in women with PCOS and overweight or obese, so the first choice in treatment of such patients should be diet and lifestyle changes, including an increase of daily physical activity.

Author Biographies

С. І. Жук, P.L. Shupik NMAPE

MD, professor, head of Obstetrics, Gynecology and Fetal Medicine Department

А. Б. Гордийчук



  1. Shestakova, I.G., Ryabinkina, Т.S. PCOS: a new look at the problem. Variety of symptoms, differential diagnosis and treatment of PCOS. Newsletter. Ed. by V.E. Radzinsky. Moscow. Editorial office of the journal StatusPraesens (2015): 24 p.
  2. Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., et al. “Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.” Fertility and Sterility, 97(2012): 28–38.
  3. National Institute of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome December 3–5, 2012. Final Report.
  4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).” Human Reproduction, 19(2004): 41–7.
  5. Conway, G., et al. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” European Journal of Endocrinology 171(2014): 1–29.
  6. Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.” Journal of Clinical Endocrinology and Metabolism, 98(2013): 4565–92.
  7. Glintborg, D., et al. “Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark.” Clin Endocrinol (Oxf) 73 (2010): 732–8.
  8. Pinola, P., Puukka, K., Piltonen, T.T., et al. “Normo- and hyperandrogenic women with polycystic ovary syndrome. Exhibit an adverse metabolic profile through life.” Fertil Steril 107.3 (2017): 788–95.
  9. The Russian Cardiology Society, etc. Diagnosis, treatment, prevention of obesity and associated diseases (project of national clinical recommendations). St. Petersburg (2017). Available from: [http:// http://www.scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf], last accessed Apr 16, 2018.
  10. Oreopoulosб A., et al. “Association between obesity and health-related quality of life in patients with coronary artery disease.” International Journal of Obesity 34.9 (2010): 1434–41.
  11. Mazaeva, N.A. “Fatty tissue, leptin and anorexia nervosa.” Psychiatry and psychopharmacotherapy named after P.B. Gannushkin 2 (2008): 18–28.
  12. Micklesfield, L.K., Goedecke, J.H., Punyanitya, M., et al. “Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat.” Obesity (Silver Spring) 20.5 (2012): 1109–14.
  13. Leptin. Laboratory reference book “Sinevo”. Available from: [https://spravochnik.synevo.ua/], last accessed Apr 16, 2018.
  14. Medical portale “Eurolab”. Available from: [http://www.eurolab.ua/], last accessed Apr 16, 2018.
  15. Chernukha, G.E., Tabeeva, G.I., Gusev, D.V., Kuznetsov, S.Y. “Evaluation of fat tissue parameters in functional hypothalamic amenorrhea.” Obstetrics and gynecology 2 (2018).
  16. Gallagher, D., et al. “Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index.” The American journal of clinical nutrition 72.3 (2000): P. 694–701.
  17. Malik, V.S., Willett, W.C., Hu, F.B.; Downey Obesity Report (2013). “Global obesity: trends, risk factors and policy implications.” Nature Reviews Endocrinology 9.1 (2013): 13–27.
  18. Okorokov, P.L., Vasyukova, O.V., Vorontsov, A.V. “Methods for estimating the amount and distribution of adipose tissue in the body and their clinical significance.” Problems of endocrinology 60.3 (2014): 53–8.
  19. Kvist, H., Chowdhury, B., Grangard, U. “Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations.” Am J Clin Nutr 48 (1988): 1351–61.
  20. Malavolti, M., Mussi, C., Poli, M., et al. “Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21–82 years.” Ann Hum Biol 30.4 (2003): 380–91. DOI: 10.1080/0301446031000095211
  21. Goran, M.I., Driscoll, P., Johnson, R., et al. “Cross-calibration of body-composition techniques against dual-energy X-ray absorptiometry in young children.” Am J Clin Nutr 63 (1996): 299–305.
  22. Yang, F., et al. “Visceral adiposity index may be a surrogate marker for the assessment of the effects of obesity on arterial stiffness.” PloS one 9.8 (2014): e104365.
  23. Villa, J., Pratley, R. “Adipose tissue dysfunction in polycystic ovary syndrome.” Current Diabetes Reports 11 (2011): 179–84.
  24. Repaci, A., Gambineri, A., Pasquali, R. “The role of low-grade inflammation in the polycystic ovary syndrome.” Molecular and Cellular Endocrinology, 15 (2011): 30–41.
  25. Kuhl, H. “Chemie und Pharmakologie von Chlormadinonacetat.” In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisieringserscheinungen. Stuttgart New York. Schattauer Verlag (1995): 1–24.
  26. Kaiser, E. “Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms.” Geburtshilfe Frauenheilkd 44.10 (1984): 651–5.
  27. Breckwoldt, M., Wieacker, P. “Hirsutismus.” In: Bettendorf, G., Breckwoldt, M., editors. Reproduktionmedizin. Stuttgart. Fischer (1989): 483–7.
  28. Breckwoldt, M., Zahradnik, H.P., Wieacker, P. “Hirsutism.” In: Orfanos, C., Happle, R., editors. Hair and hair diseases. Berlin. SpringerVerlag (1990): 777–89.
  29. Worret, I., Arp, W., Zahradnik, H., et al. “Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).” Dermatology 203.1 (2001): 38–44.
  30. Schramm, G., Steffens, D. “A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and antiandrogenic properties.” Contraception 67.4 (2003): 305–12.
  31. Zahradnik, H., Goldberg, J., Andreas, J. “Efficacy and safety of the new antiandrogenic oral contraceptive Belara.” Contraception 57.2 (1998): 103–9.
  32. Schramm, G., Steffens, D. “Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®). Results of a post-marketing surveillance study.” Clin Drug Invest 22 (2002): 221–31.
  33. Schramm, G., Heckes, B. “Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.” Contraception 76.2 (2007): 84–90.
  34. Uras, R., Orru, M., Etzi, R., et al. “Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 meg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass.” Contraception 79.2 (2009): 117–21.
  35. Study KF 5025/02. Effect on haemostasis and metabolic parameters. Data on file. FO-KL354/A.
  36. Global analysis of safety for Belara®. Data on file.



How to Cite

Жук, С. І., & Гордийчук, А. Б. (2018). PCOS: phenotypes, visceral obesity and a personalized approach in the prescription of COC. REPRODUCTIVE ENDOCRINOLOGY, (40), 34–41. https://doi.org/10.18370/2309-4117.2018.40.34-41




Most read articles by the same author(s)